BioSpace News Archive

Astellas Pharma Inc. will share new research during the 2022 American Society of Clinical Oncology Annual Meeting from June 3-7 and the European Hematology Association 2022 Hybrid Congress from June 9-12.

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that an abstract providing safety and efficacy data from the ongoing CTX130™ clinical trial for patients with T-cell lymphoma has been accepted for oral presentation at the Annual European Hematology Association (EHA) 2022 Hybrid Congress.

NeoTX announced the acquisition of InterX. InterX, is a drug discovery company utilizing advanced proprietary tools of biomolecular computation for the discovery and design of novel therapeutic molecules based on Nobel Prize Laureate Prof Michael Levitt’s discoveries.

Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), today announced that results from the follicular lymphoma (“FL”) cohort of the ongoing Phase 1/2 clinical trial of MB-106, a CD20-targeted, autologous CAR T cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin lymphomas (“B-NHLs”) and chronic lymphocytic leukemia (“CLL”) were selected for an oral presentation at the European Hematology Association 2022 Hybrid Congress.

Lunaphore, and Indica Labs, today announced a partnership to co-market an end-to-end solution that combines Lunaphore’s flagship COMET™ spatial biology platform and Indica’s HALO® and HALO AI™ digital pathology image analysis software.

Karyopharm Therapeutics Inc. (NASDAQ: KPTI), today announced that initial data from a Phase 1 portion of the Ph 1/2 study evaluating selinexor in combination with ruxolitinib in patients with treatment-naïve myelofibrosis has been selected for a poster presentation at the European Hematology Association (EHA) 2022 Hybrid Congress taking place June 9-12, 2022, in Vienna, Austria.

John Molinaro is a Board Certified Behaviour Analyst (BCBA) with a Master’s degree in Applied Behaviour Analysis, as well as a Bachelor’s degree in Psychology. For more than 13 years, Mr. Molinaro has dedicated his life to supporting children, youth and adults challenged with physical and cognitive disabilities

Brainlab, a digital medical technology company, announced today the majority acquisition of medPhoton GmbH, a Salzburg, Austria-based company, that develops and manufactures robotic imaging solutions for image guided radiation therapy and surgery.

Chimeric antigen receptor (CAR) T-cell therapy is a novel class of immunotherapy which involves genetically engineered T-cells to allow recognizing and targeting the tumor cell.

By bringing together experts for rare diseases, WODA has capabilities to provide all the services necessary for orphan medicines to reach patients in need, replacing local branches of global distributors or multinational companies.